Navigating midlife and menopause often involves exploring various options to support well-being. Black cohosh is one such botanical that women frequently consider. Understanding the regulatory landscape and safety information surrounding black cohosh is an important part of making informed personal health choices.
While black cohosh has been a subject of research, it’s crucial to be aware of the FDA’s perspective and any associated warnings. This article aims to provide clear, evidence-based information on black cohosh supplements, focusing on safety and regulatory considerations.
Is Black Cohosh Approved by the FDA?
In the United States, dietary supplements, including black cohosh, are regulated by the FDA under the Dietary Supplement Health and Education Act (DSHEA) of 1994. It’s important to understand that DSHEA places dietary supplements in a different category than prescription or over-the-counter medications. Unlike pharmaceutical drugs, dietary supplements do not require pre-market approval from the FDA before they can be sold.
This means that the FDA does not “approve” black cohosh supplements in the same way it approves a new drug. Instead, manufacturers are responsible for ensuring the safety and labeling accuracy of their products before they go to market. The FDA’s role primarily involves monitoring the safety of supplements after they are on the market and taking action against unsafe products or those with false or misleading claims.
FDA and Liver Health Concerns with Black Cohosh
One of the most significant safety concerns that has prompted attention from regulatory bodies, including the FDA, is the potential for liver-related issues associated with black cohosh. There have been case reports linking black cohosh consumption to liver toxicity [1]. These reports describe various degrees of liver injury, though a definitive causal link has been challenging to establish in all instances.
The United States Pharmacopeia (USP) has conducted reviews of black cohosh case reports related to liver health [1]. While the precise mechanisms are still being investigated, the accumulation of such reports has led to recommendations for cautionary labeling. The FDA encourages manufacturers to include warnings about potential liver issues on black cohosh product labels to inform consumers of this risk.
Labeling and Quality of Black Cohosh Supplements
The FDA’s regulations for dietary supplements emphasize that product labels should not make claims to diagnose, mitigate, treat, or cure a disease. Instead, labels can make structure/function claims, such as “supports menopausal comfort,” provided they are truthful and not misleading. However, ensuring the quality and purity of black cohosh supplements can be a challenge.
Studies have indicated that not all black cohosh products on the market contain the advertised ingredients or concentrations. Some products may be adulterated with other plant species or contain little to no active black cohosh components. This inconsistency in product quality can make it difficult for consumers to know what they are truly taking and may complicate assessments of safety and effectiveness. The FDA does have the authority to take action against manufacturers whose products are mislabeled or adulterated.
General Safety Considerations and Adverse Effects
Beyond liver concerns, other adverse effects have been reported with black cohosh use. These can include gastrointestinal upset, headache, and rash [2]. While generally considered mild, any unusual or persistent symptoms should be discussed with a healthcare provider.
It’s also important to consider potential interactions with other medications. Black cohosh may interact with certain drugs, including hormone therapies [3]. Women who are taking prescription medications or other supplements should consult their healthcare provider before adding black cohosh to their regimen to avoid potential adverse interactions.
The FDA’s Role in Post-Market Surveillance
Since dietary supplements do not undergo pre-market approval, the FDA’s primary mechanism for ensuring safety is through post-market surveillance. This involves monitoring adverse event reports submitted by consumers, healthcare professionals, and manufacturers. When the FDA identifies a pattern of adverse events or serious safety concerns, it can take regulatory action.
Actions can include issuing warning letters to manufacturers, requiring product recalls, or pursuing enforcement actions against companies that violate regulations. The FDA also provides guidance to the industry to help ensure compliance with good manufacturing practices, which aim to ensure the identity, purity, quality, strength, and composition of dietary supplements.
References
- United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity. Menopause (New York, N.Y.), 2008
- Review of black cohosh-induced toxicity and adverse clinical effects. Journal of environmental science and health. Part C, Toxicology and carcinogenesis, 2025
- Hormone Therapy and Other Treatments for Symptoms of Menopause. American family physician, 2016
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
